TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02617 TRANSTHERA-B

Noon Closed 10-16 11:59:58

9.430

+0.295

+3.23%

High9.455	Low9.260	Vol994.00K
Open9.330	D1 Closing9.135	Amplitude2.13%
Mkt Cap3.84B	Tradable Cap2.94B	Total Shares407.00M
T/O9.29M	T/O Rate0.32%	Tradable Shares312.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":9.43,"timestamp":1792123198379,"preClose":9.135,"halted":0,"volume":994000,"delay":0,"changeRate":0.03229337712096332,"floatShares":312000000,"shares":407000000,"eps":-0.8916835521514277,"marketStatus":"Noon Closed","change":0.295,"latestTime":"10-16 11:59:58","open":9.33,"high":9.455,"low":9.26,"amount":9291200,"amplitude":0.021346,"askPrice":9.43,"askSize":4000,"bidPrice":9.35,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.7891094386903873,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1792126800000},"marketStatusCode":3,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":9.135,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":0.727696,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617","defaultTab":"news","newsList":[{"id":"1143122994","title":"Hong Kong Market Pulse: TRANSTHERA-B Soars Over 11% on Phase II Trial Progress and Commercial Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1143122994","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143122994?lang=en_us&edition=fundamental","pubTime":"2026-09-21 10:52","pubTimestamp":1789959135,"startTime":"0","endTime":"0","summary":"Shares of TRANSTHERA-B (02617) surged more than 11% in Hong Kong trading on Thursday, with the stock last changing hands at HK$11.17, up 11.37%, on turnover of HK$103 million.According to a company...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","KCAI","BK1161","VXUS","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923337","title":"TransThera Sciences Doses First Patient in Prostate Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923337","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923337?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:53","pubTimestamp":1789732426,"startTime":"0","endTime":"0","summary":"TransThera Sciences   dosed the first patient in a phase II clinical trial of tinengotinib in China, according to a Friday Hong Kong bourse filing.The trial is testing the safety and efficacy of the drug in combination with novel hormonal therapy for pretreated and progressed metastatic castration-resistant prostate cancer.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668940056","title":"TransThera's Biliary Tract Cancer Drug Included in Clinical Oncology Society's Guidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2668940056","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668940056?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:11","pubTimestamp":1789729896,"startTime":"0","endTime":"0","summary":"TransThera Sciences 's  Yochanra has been included in the Chinese Society of Clinical Oncology's guidelines for the diagnosis and treatment of biliary tract cancers.The inclusion is for the drug as a Class II recommendation Class 2A for the treatment of advanced biliary tract cancers, a Friday bourse filing showed.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180908822","title":"TRANSTHERA-B’s Tinengotinib Secures Class 2A Spot in 2026 CSCO Biliary Tract Cancer Guidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=1180908822","media":"Bulletin Express","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180908822?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:04","pubTimestamp":1789729474,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (TransThera Sciences [Nanjing], Inc.) announced that YOCHANRA (tinengotinib), its self-developed multi-target small-molecule kinase inhibitor, has been incorporated into the 2026 Chinese...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138364495","title":"Transthera-B Doses First Patient in Phase II Trial of Tinengotinib Combined with Novel Endocrine Therapy for Advanced Metastatic Castration-Resistant Prostate Cancer in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1138364495","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138364495?lang=en_us&edition=fundamental","pubTime":"2026-09-18 18:58","pubTimestamp":1789729102,"startTime":"0","endTime":"0","summary":"Transthera-B (02617) has announced that the first patient has been dosed in its Phase II clinical trial in China evaluating tinengotinib (Jentai®; Tinengotinib, TT-00420) combined with novel...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDTX","BK1161","BMED","02617","IBBQ","IBBJ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668940818","title":"Transthera Sciences (Nanjing) - Yochanra (Tinengotinib) Included in Csco Guidelines for Advanced Biliary Tract Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2668940818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668940818?lang=en_us&edition=fundamental","pubTime":"2026-09-18 18:45","pubTimestamp":1789728314,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN45A0E9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115766616","title":"TransThera Sciences Posts Steady August 2026 Share Capital; Confirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1115766616","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115766616?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:23","pubTimestamp":1788348190,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has released its Monthly Return for Equity Issuer for the period ended 31 August 2026, showing no changes in either authorised or issued share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662308477","title":"TransThera Sciences (Nanjing) (SEHK:2617) Stock Sees Revenue Emerge As Losses Persist","url":"https://stock-news.laohu8.com/highlight/detail?id=2662308477","media":"Simply Wall St.","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662308477?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:35","pubTimestamp":1787834115,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) stock came into this earnings print bruised, with the 90 day return deep in the red despite a small bounce over the past week and month. Yet the latest H1 2026 numbers tell a more nuanced story. Revenue landed at C¥35.455 million, a clear shift for a company that previously reported no sales, while earnings still showed a sizeable loss with basic earnings per share of C¥0.24 in the red. The real question for the market now is whether this early top line traction...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2617/transthera-sciences-nanjing-shares/news/transthera-sciences-nanjing-sehk2617-stock-sees-revenue-emer","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2617/transthera-sciences-nanjing-shares/news/transthera-sciences-nanjing-sehk2617-stock-sees-revenue-emer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165891458","title":"TransThera Sciences turns first-half revenue positive on licensing deal, narrows loss to RMB95.47 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1165891458","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165891458?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:42","pubTimestamp":1787740943,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. reported its first meaningful revenue and a sharply reduced interim loss for the six months ended 30 June 2026, driven by an upfront payment from a licensing...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"TransThera Sciences turns first-half revenue positive on licensing deal, narrows loss to RMB95.47 million","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797038","title":"Transthera Sciences’ Tinengotinib Wins Conditional China NMPA Approval for Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797038","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797038?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:24","pubTimestamp":1787739876,"startTime":"0","endTime":"0","summary":"Transthera Sciences’ tinengotinib wins conditional China NMPA approval for cholangiocarcinomaTransthera Sciences’ tinengotinib won conditional NMPA approval on Aug. 6, 2026 for FGFR2 fusion/rearrangem","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL2YKGVJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662977247","title":"Transthera Sciences FY26 H1 Net Loss Narrows to RMB 95.47 Million; Revenue Rises to RMB 35.46 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662977247","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662977247?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:23","pubTimestamp":1787739806,"startTime":"0","endTime":"0","summary":"Transthera Sciences FY26 H1 net loss narrows to RMB 95.47 million; revenue rises to RMB 35.46 millionTransthera Sciences posted a net loss of RMB 95.47 million, narrowing from RMB 122.87 million a yea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL2bv27N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127962724","title":"TRANSTHERA-B: Ching Fen Chan Tan Disposes of Shares, Long Position Falls to 5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127962724","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127962724?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:16","pubTimestamp":1787649417,"startTime":"0","endTime":"0","summary":"On August 20, 2026, Ching Fen Chan Tan sold 1.00 million shares of TRANSTHERA-B (H shares) at an average of HKD 10.5891 per share, involving about HKD 10.59 million.Prior to the disposal, Ching Fen...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138671629","title":"TRANSTHERA-B: Ghalibo (PTC) Limited Disposes of Shares, Long Position Falls to 5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138671629","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138671629?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:14","pubTimestamp":1787649247,"startTime":"0","endTime":"0","summary":"On August 20, 2026, Ghalibo (PTC) Limited sold 1.00 million shares of TRANSTHERA-B (02617) at an average of HKD 10.59 per share, involving about HKD 10.59 million.Prior to the disposal, Ghalibo (PTC)...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100275431","title":"TRANSTHERA-B: Morningside Venture (I) Investments Limited Disposes of Shares, Long Position Falls to 5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100275431","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100275431?lang=en_us&edition=fundamental","pubTime":"2026-08-24 17:18","pubTimestamp":1787563091,"startTime":"0","endTime":"0","summary":"Morningside Venture (I) Investments Limited sold 1.00 million shares of TRANSTHERA-B at an average of HKD 10.5891 per share on August 20, 2026, involving about HKD 10.59 million.Prior to the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117316614","title":"TRANSTHERA-B: Morningside Bio-Ventures Limited Disposes of Shares, Long Position Falls to 5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117316614","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117316614?lang=en_us&edition=fundamental","pubTime":"2026-08-24 17:17","pubTimestamp":1787563036,"startTime":"0","endTime":"0","summary":"On August 20, 2026, Morningside Bio-Ventures Limited sold 1.00 million shares of TRANSTHERA-B (02617) stock at an average of HKD 10.5891 per share, involving about HKD 10.59 million.Prior to the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131549459","title":"TransThera Sciences Schedules 26 August Board Meeting to Review 1H 2026 Results and Consider Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1131549459","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131549459?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:27","pubTimestamp":1786699647,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. has notified shareholders that its board of directors will convene on 26 August 2026 in Hong Kong. The meeting’s agenda includes three primary items: 1. Review and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659114041","title":"TransThera Sciences Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659114041","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659114041?lang=en_us&edition=fundamental","pubTime":"2026-08-14 16:58","pubTimestamp":1786697918,"startTime":"0","endTime":"0","summary":"TransThera Sciences schedules board meeting to review interim resultsTransThera Sciences (Nanjing) schedules a board meeting for Aug. 26, 2026 to review interim results for the six months ended June 3","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL7R5pD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120497991","title":"TRANSTHERA-B: Future Industry Investment Fund II (Limited Partnership) Disposes of Shares, Long Position Falls to 5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120497991","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120497991?lang=en_us&edition=fundamental","pubTime":"2026-08-10 17:11","pubTimestamp":1786353113,"startTime":"0","endTime":"0","summary":"Future Industry Investment Fund II (Limited Partnership) sold 1.77 million shares of TRANSTHERA-B stock at an average of HKD 13.74 per share on August 7, 2026, involving about HKD 24.36 million.Prior...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657973826","title":"China NMPA Approves TransThera’s Yochanra for FGFR Inhibitor-Resistant Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657973826","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657973826?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:45","pubTimestamp":1786085149,"startTime":"0","endTime":"0","summary":"China NMPA approves TransThera’s Yochanra for FGFR inhibitor-resistant cholangiocarcinomaChina’s NMPA cleared TransThera’s Yochanra for FGFR2 fusion- or rearrangement-positive advanced cholangiocarcin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL93NWZp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174583245","title":"TRANSTHERA-B Shares Jump Over 12% in Morning Trading After Core Drug Tenagotinib Gets Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1174583245","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174583245?lang=en_us&edition=fundamental","pubTime":"2026-08-07 09:50","pubTimestamp":1786067457,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) opened more than 28% higher in early trading, later trimming gains to trade up 12.06% at HK$12.92, with turnover reaching HK$226 million.The company announced last night that its...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.0929},{"period":"1month","weight":-0.0425},{"period":"3month","weight":-0.0504},{"period":"6month","weight":-0.868},{"period":"1year","weight":-0.9195},{"period":"ytd","weight":-0.9205}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":-0.0245},{"period":"3month","weight":-0.0203},{"period":"6month","weight":-0.0802},{"period":"1year","weight":-0.0713},{"period":"ytd","weight":-0.0612}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Company's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The Company's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). It is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.","exchange":"SEHK","name":"TRANSTHERA-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TRANSTHERA-B(02617) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TRANSTHERA-B,02617,TRANSTHERA-B股票,TRANSTHERA-B股票老虎,TRANSTHERA-B股票老虎国际,TRANSTHERA-B行情,TRANSTHERA-B股票行情,TRANSTHERA-B股价,TRANSTHERA-B股市,TRANSTHERA-B股票价格,TRANSTHERA-B股票交易,TRANSTHERA-B股票购买,TRANSTHERA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TRANSTHERA-B(02617) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}